Worth reading
32Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Who is moving to which position
Resolved 24 April 2026Incoming appointee
1 itemScheduled Appointment DateAfter the conclusion of the 76th Annual General Meeting of Shareholders scheduled for 16 June 2026. The appointment is scheduled to be formally decided following a resolution at a meeting of the Board of Directors to be held after this meeting.
Aoyagi Katsumi (青柳克己)
Previous positionFujirebio Co., Ltd., Managing Director and General Manager of the Research and Development Division (currently); 富士レビオ・ホールディングス（株）, Director (currently); （株）先端生命科学研究所, Representative Director and President (currently)
New positionExecutive Officer, in charge of research and development
生年月日 10 August 1962
Departing officer
1 itemDate of departureAfter the conclusion of the 76th Annual General Meeting of Shareholders scheduled for 16 June 2026
Takeuchi Shigekazu (竹内成和), Kitamura Naoki (北村直樹), Omi Kazuya (小見和也), Shimizu Toshihiko (清水俊彦)Stepping down
Former PositionTakeuchi Shigekazu (竹内成和): Executive Officer; Kitamura Naoki (北村直樹): Senior Executive Officer, in charge of finance; Omi Kazuya (小見和也): Executive Officer, in charge of research and development; Shimizu Toshihiko (清水俊彦): Executive Officer, in charge of IT
Shareholders’ meeting approvalRequired. Although the name of the proposal is not specified, the appointments are scheduled to take effect after the conclusion of the 76th Annual General Meeting of Shareholders scheduled for 16 June 2026.
| Item | Details |
|---|---|
| Resolution date | 24 April 2026 |
| Scheduled Appointment Date | After the conclusion of the 76th Annual General Meeting of Shareholders scheduled for 16 June 2026. The appointment is scheduled to be formally decided following a resolution at a meeting of the Board of Directors to be held after this meeting. |
| Date of departure | After the conclusion of the 76th Annual General Meeting of Shareholders scheduled for 16 June 2026 |
| Name of appointee | Aoyagi Katsumi (青柳克己) |
| Appointee's new position | Executive Officer, in charge of research and development |
| Appointee's previous position | Fujirebio Co., Ltd., Managing Director and General Manager of the Research and Development Division (currently); 富士レビオ・ホールディングス（株）, Director (currently); （株）先端生命科学研究所, Representative Director and President (currently) |
| Appointee's date of birth | 10 August 1962 |
| Name of departing officer | Takeuchi Shigekazu (竹内成和), Kitamura Naoki (北村直樹), Omi Kazuya (小見和也), Shimizu Toshihiko (清水俊彦) |
| Former position of departing officer | Takeuchi Shigekazu (竹内成和): Executive Officer; Kitamura Naoki (北村直樹): Senior Executive Officer, in charge of finance; Omi Kazuya (小見和也): Executive Officer, in charge of research and development; Shimizu Toshihiko (清水俊彦): Executive Officer, in charge of IT |
| Subject to Approval by the General Meeting of Shareholders | Required. Although the name of the proposal is not specified, the appointments are scheduled to take effect after the conclusion of the 76th Annual General Meeting of Shareholders scheduled for 16 June 2026. |
Items this document does not state (11)
Year the appointee joined the CompanyNumber of shares held by the appointeeNew position of departing officerReason for departureWhether the incumbent will remain in officeReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance Structure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No specific reason for the changes is stated.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.